Fig. 1: Seroconversion in patients with cancer after COVID-19 vaccination.
a, Sampling and analysis schema in the CAPTURE study. Baseline samples were collected immediately before the first dose. Follow-up samples were collected 2–4 weeks after the first dose (follow-up (FU)1), on the day of and immediately before the second dose (FU2; that is, the additional time point after the first dose implemented due to the delayed 12-week dosing interval) and 2–4 weeks after the second dose (FU3). S1-reactive antibody tests (that is, seroconversion) and NAb assays were performed in all available follow-up samples from 585 patients. b, Proportion of infection-naive patients (n = 328, 323, 256 and 312 patients at baseline, FU1, FU2 and FU3, respectively) with S1-reactive antibodies at each time point. Differences were analyzed using the χ2 test. P values < 0.05 were considered significant. c, Proportion of infection-naive patients with S1-reactive antibodies grouped by solid (n = 270, 234, 192 and 234 patients at baseline, FU1, FU2 and FU3, respectively) and hematological malignancies (n = 58, 89, 64 and 78 patients at baseline, FU1, FU2 and FU3, respectively). Differences were analyzed by the χ2 test. P values < 0.05 were considered significant. FU1, 21–56 d after the first vaccine; FU2, 14–28 d before the second vaccine; FU3, 14–28 d after the second vaccine.
